1 of 4
The global BCG vaccines sales market was valued at $45 million in 2017, and is estimated to reach $65 million by 2025, growing at a CAGR of 4.2% from 2018 to 2025.
BCG vaccine is a live attenuated vaccine used for the prevention of tuberculosis. It is administered to newborns from tuberculosis and leprosy prevalent regions. This vaccine is generally administered to children at birth in countries with high incidence of TB. However, in low incidence regions, only children at high risk are typically immunized, whereas adults are generally not immunized. However, adults (up to the age of 35) who are frequently exposed to drug-resistant TB may also be given BCG vaccine.
Major factors that drive the market growth are increase in the prevalence of tuberculosis and rise in technological advancements in vaccine research. Moreover, increase in government initiatives and focus on immunization programs globally boost the market growth. However, side-effects and a global shortage of BCG vaccine restrain the market growth. Furthermore, untapped market potential in developing regions is expected to provide lucrative opportunities for the market development.
This report segments the BCG vaccines sales market based on drug type, usage, end user, and region to provide a detailed assessment of the market. Based on drug type, it is bifurcated into immune BCG and therapy BCG. On the basis of usage, the market is categorized into tuberculosis and bladder cancer. Based on end user, it is segmented into adults and pediatrics. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
By Drug Type
o Canada
o Mexico
o France
o UK
o Italy
o Spain
o Rest of Europe
o China
o India
o Rest of Asia-Pacific
o Middle East
o Africa
LIST OF KEY PLAYERS PROFILED IN THE REPORT (DEVICE PROVIDERS)
BCG vaccine is a live attenuated vaccine used for the prevention of tuberculosis. It is administered to newborns from tuberculosis and leprosy prevalent regions. This vaccine is generally administered to children at birth in countries with high incidence of TB. However, in low incidence regions, only children at high risk are typically immunized, whereas adults are generally not immunized. However, adults (up to the age of 35) who are frequently exposed to drug-resistant TB may also be given BCG vaccine.
Major factors that drive the market growth are increase in the prevalence of tuberculosis and rise in technological advancements in vaccine research. Moreover, increase in government initiatives and focus on immunization programs globally boost the market growth. However, side-effects and a global shortage of BCG vaccine restrain the market growth. Furthermore, untapped market potential in developing regions is expected to provide lucrative opportunities for the market development.
This report segments the BCG vaccines sales market based on drug type, usage, end user, and region to provide a detailed assessment of the market. Based on drug type, it is bifurcated into immune BCG and therapy BCG. On the basis of usage, the market is categorized into tuberculosis and bladder cancer. Based on end user, it is segmented into adults and pediatrics. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the BCG vaccines sales market along with the current trends and future estimations to elucidate the imminent investment pockets.
- A quantitative analysis from 2017 to 2025 is discussed to enable the stakeholders to capitalize on the prevailing market opportunities.
- In-depth analysis of BCG vaccines sales based on drug type such as immune BCG and therapy BCG is carried out in the report.
- The global BCG vaccines sales market scenario is comprehensively analyzed in accordance to the key cities.
By Drug Type
- Immune BCG
- Therapy BCG
- Tuberculosis
- Bladder Cancer
- Pediatrics
- Adults
- North America
o Canada
o Mexico
- Europe
o France
o UK
o Italy
o Spain
o Rest of Europe
- Asia-Pacific
o China
o India
o Rest of Asia-Pacific
- LAMEA
o Middle East
o Africa
LIST OF KEY PLAYERS PROFILED IN THE REPORT (DEVICE PROVIDERS)
- AJ Vaccines
- China National Pharmaceutical Group Corporation (Sinopharm)
- Greensignal Bio Pharma Limited
- Intervax Ltd
- Japan BCG Laboratory
- Merck & Company Inc
- Sanofi S.A
- Serum Institute of India Pvt. Ltd
- Statens Serum Institute
- Shanyao Group
- Shanghai Institute of Biological Products
- BCG Vaccine Laboratory India
Note: Product cover images may vary from those shown
2 of 4
Chapter: 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
Chapter: 2: EXECUTIVE SUMMARY
2.1. CXO perspective
Chapter: 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Market dynamics
3.3.1. Drivers
3.3.1.1. High prevalence of tuberculosis worldwide
3.3.1.2. Rise in number of drug-resistant tuberculosis cases
3.3.2. Opportunity
3.3.2.1. Initiatives by United Nations (UN) for TB prevention worldwide
3.3.3. Challenge
3.3.3.1. Replacement for BCG vaccine
Chapter: 4: BCG VACCINE SALES MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Immune BCG
4.2.1. Key market trends, growth factors, and opportunities
4.3. Therapy BCG
4.3.1. Key market trends, growth factors, and opportunities
Chapter: 5: BCG VACCINE SALES MARKET, BY USAGE
5.1. Overview
5.1.1. Market size and forecast
5.2. Tuberculosis
5.2.1. Key market trends, growth factors, and opportunities
5.3. Bladder Cancer
5.3.1. Key market trends, growth factors, and opportunities
Chapter: 6: GLOBAL BCG VACCINES SALES MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Pediatrics
6.2.1. Key market trends, growth factors, and opportunities
6.3. Adults
6.3.1. Key market trends, growth factors, and opportunities
Chapter: 7: BCG VACCINES SALES MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key growth factors and opportunities
7.2.2. Market size and forecast, by drug type
7.2.3. Market size and forecast, by usage
7.2.4. Market size and forecast, by end user
7.2.5. Market size and forecast, by country
7.2.5.1. U.S. market size and forecast, by drug type
7.2.5.2. U.S. market size and forecast, by usage
7.2.5.3. U.S. market size and forecast, by end user
7.2.5.4. Canada market size and forecast, by drug type
7.2.5.5. Canada market size and forecast, by usage
7.2.5.6. Canada market size and forecast, by end user
7.2.5.7. Mexico market size and forecast, by drug type
7.2.5.8. Mexico market size and forecast, by usage
7.2.5.9. Mexico market size and forecast, by end user
7.2.5.10. Europe
7.2.6. Key market trends growth factors and opportunities
7.2.7. Market size and forecast, by drug type
7.2.8. Market size and forecast, by usage
7.2.9. Market size and forecast, by end user
7.2.10. Market size and forecast, by country
7.2.10.1. Germany market size and forecast, by drug type
7.2.10.2. Germany market size and forecast, by usage
7.2.10.3. Germany market size and forecast, by end user
7.2.10.4. France market size and forecast, by drug type
7.2.10.5. France market size and forecast, by usage
7.2.10.6. France market size and forecast, by end user
7.2.10.7. UK market size and forecast, by drug type
7.2.10.8. UK market size and forecast, by usage
7.2.10.9. UK market size and forecast, by end user
7.2.10.10.Italy market size and forecast, by drug type
7.2.10.11.Italy market size and forecast, by usage
7.2.10.12.Italy market size and forecast, by end user
7.2.10.13.Spain market size and forecast, by drug type
7.2.10.14.Spain market size and forecast, by usage
7.2.10.15.Spain market size and forecast, by end user
7.2.10.16. Rest of Europe market size and forecast, by drug type
7.2.10.17.Rest of Europe market size and forecast, by usage
7.2.10.18.Rest of Europe market size and forecast, by end user
7.3. Asia-Pacific
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by drug type
7.3.3. Market size and forecast, by usage
7.3.4. Market size and forecast, by end user
7.3.5. Market size and forecast, by country
7.3.5.1. Japan market size and forecast, by drug type
7.3.5.2. Japan market size and forecast, by usage
7.3.5.3. Japan market size and forecast, by end user
7.3.5.4. China market size and forecast, by drug type
7.3.5.5. China market size and forecast, by usage
7.3.5.6. China market size and forecast, by end user
7.3.5.7. India market size and forecast, by drug type
7.3.5.8. India market size and forecast, by usage
7.3.5.9. India market size and forecast, by end user
7.3.5.10. Rest of Asia-Pacific market size and forecast, by drug type
7.3.5.11. Rest of Asia-Pacific market size and forecast, by usage
7.3.5.12. Rest of Asia-Pacific market size and forecast, by end user
7.4. LAMEA
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by drug type
7.4.3. Market size and forecast, by usage
7.4.3.1. LAMEA market size and forecast, by end user
7.4.4. Market size and forecast, by country
7.4.4.1. Latin America market size and forecast, by drug type
7.4.4.2. Latin America market size and forecast, by usage
7.4.4.3. Latin America market size and forecast, by end user
7.4.4.4. Middle East market size and forecast, by drug type
7.4.4.5. Middle East market size and forecast, by usage
7.4.4.6. Middle East market size and forecast, by end user
7.4.4.7. Africa market size and forecast, by drug type
7.4.4.8. Africa market size and forecast, by usage
7.4.4.9. Africa market size and forecast, by end user
Chapter: 8: COMPANY PROFILES
8.1. AJ Vaccines
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.2. China National Pharmaceutical Group Corporation (Sinopharm)
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.3. GREENSIGNAL BIO PHARMA LIMITED
8.3.1. Company overview
8.3.2. GSBPL: company snapshot
8.3.3. Operating business segments
8.3.4. Key strategic moves and development
8.3.5. Product portfolio
8.4. INTERVAX LTD
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Key strategic moves and developments
8.5. JAPAN BCG LABORATORY
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.6. MERCK & COMPANY INC
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. SANOFI S.A.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. SERUM INSTITUTE OF INDIA PVT. LTD
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Key strategic moves and developments
8.9. STATENS SERUM INSTITUTE
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Key strategic moves and developments
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
Chapter: 2: EXECUTIVE SUMMARY
2.1. CXO perspective
Chapter: 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Market dynamics
3.3.1. Drivers
3.3.1.1. High prevalence of tuberculosis worldwide
3.3.1.2. Rise in number of drug-resistant tuberculosis cases
3.3.2. Opportunity
3.3.2.1. Initiatives by United Nations (UN) for TB prevention worldwide
3.3.3. Challenge
3.3.3.1. Replacement for BCG vaccine
Chapter: 4: BCG VACCINE SALES MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Immune BCG
4.2.1. Key market trends, growth factors, and opportunities
4.3. Therapy BCG
4.3.1. Key market trends, growth factors, and opportunities
Chapter: 5: BCG VACCINE SALES MARKET, BY USAGE
5.1. Overview
5.1.1. Market size and forecast
5.2. Tuberculosis
5.2.1. Key market trends, growth factors, and opportunities
5.3. Bladder Cancer
5.3.1. Key market trends, growth factors, and opportunities
Chapter: 6: GLOBAL BCG VACCINES SALES MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Pediatrics
6.2.1. Key market trends, growth factors, and opportunities
6.3. Adults
6.3.1. Key market trends, growth factors, and opportunities
Chapter: 7: BCG VACCINES SALES MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key growth factors and opportunities
7.2.2. Market size and forecast, by drug type
7.2.3. Market size and forecast, by usage
7.2.4. Market size and forecast, by end user
7.2.5. Market size and forecast, by country
7.2.5.1. U.S. market size and forecast, by drug type
7.2.5.2. U.S. market size and forecast, by usage
7.2.5.3. U.S. market size and forecast, by end user
7.2.5.4. Canada market size and forecast, by drug type
7.2.5.5. Canada market size and forecast, by usage
7.2.5.6. Canada market size and forecast, by end user
7.2.5.7. Mexico market size and forecast, by drug type
7.2.5.8. Mexico market size and forecast, by usage
7.2.5.9. Mexico market size and forecast, by end user
7.2.5.10. Europe
7.2.6. Key market trends growth factors and opportunities
7.2.7. Market size and forecast, by drug type
7.2.8. Market size and forecast, by usage
7.2.9. Market size and forecast, by end user
7.2.10. Market size and forecast, by country
7.2.10.1. Germany market size and forecast, by drug type
7.2.10.2. Germany market size and forecast, by usage
7.2.10.3. Germany market size and forecast, by end user
7.2.10.4. France market size and forecast, by drug type
7.2.10.5. France market size and forecast, by usage
7.2.10.6. France market size and forecast, by end user
7.2.10.7. UK market size and forecast, by drug type
7.2.10.8. UK market size and forecast, by usage
7.2.10.9. UK market size and forecast, by end user
7.2.10.10.Italy market size and forecast, by drug type
7.2.10.11.Italy market size and forecast, by usage
7.2.10.12.Italy market size and forecast, by end user
7.2.10.13.Spain market size and forecast, by drug type
7.2.10.14.Spain market size and forecast, by usage
7.2.10.15.Spain market size and forecast, by end user
7.2.10.16. Rest of Europe market size and forecast, by drug type
7.2.10.17.Rest of Europe market size and forecast, by usage
7.2.10.18.Rest of Europe market size and forecast, by end user
7.3. Asia-Pacific
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by drug type
7.3.3. Market size and forecast, by usage
7.3.4. Market size and forecast, by end user
7.3.5. Market size and forecast, by country
7.3.5.1. Japan market size and forecast, by drug type
7.3.5.2. Japan market size and forecast, by usage
7.3.5.3. Japan market size and forecast, by end user
7.3.5.4. China market size and forecast, by drug type
7.3.5.5. China market size and forecast, by usage
7.3.5.6. China market size and forecast, by end user
7.3.5.7. India market size and forecast, by drug type
7.3.5.8. India market size and forecast, by usage
7.3.5.9. India market size and forecast, by end user
7.3.5.10. Rest of Asia-Pacific market size and forecast, by drug type
7.3.5.11. Rest of Asia-Pacific market size and forecast, by usage
7.3.5.12. Rest of Asia-Pacific market size and forecast, by end user
7.4. LAMEA
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by drug type
7.4.3. Market size and forecast, by usage
7.4.3.1. LAMEA market size and forecast, by end user
7.4.4. Market size and forecast, by country
7.4.4.1. Latin America market size and forecast, by drug type
7.4.4.2. Latin America market size and forecast, by usage
7.4.4.3. Latin America market size and forecast, by end user
7.4.4.4. Middle East market size and forecast, by drug type
7.4.4.5. Middle East market size and forecast, by usage
7.4.4.6. Middle East market size and forecast, by end user
7.4.4.7. Africa market size and forecast, by drug type
7.4.4.8. Africa market size and forecast, by usage
7.4.4.9. Africa market size and forecast, by end user
Chapter: 8: COMPANY PROFILES
8.1. AJ Vaccines
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.2. China National Pharmaceutical Group Corporation (Sinopharm)
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.3. GREENSIGNAL BIO PHARMA LIMITED
8.3.1. Company overview
8.3.2. GSBPL: company snapshot
8.3.3. Operating business segments
8.3.4. Key strategic moves and development
8.3.5. Product portfolio
8.4. INTERVAX LTD
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Key strategic moves and developments
8.5. JAPAN BCG LABORATORY
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.6. MERCK & COMPANY INC
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. SANOFI S.A.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. SERUM INSTITUTE OF INDIA PVT. LTD
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Key strategic moves and developments
8.9. STATENS SERUM INSTITUTE
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Key strategic moves and developments
Note: Product cover images may vary from those shown
3 of 4
According to this report titled 'Global BCG Vaccines Sales Market by Drug Type, Usage, End User, Region: Global Opportunity Analysis and Industry Forecast, 2018 - 2025', the Global BCG vaccines sales market size is expected to increase and is anticipated to reach $65 million by 2025, registering a CAGR of 4.2% from 2019 to 2025.
BCG vaccine is a live attenuated vaccine used for the prevention of tuberculosis. The types of BCG drugs include immune BCG and therapy BCG. The BCG vaccines sales market growth has increased owing to gained prominence in the recent years due to high prevalence of tuberculosis worldwide and rise in number of drug-resistant tuberculosis cases. However, replacement for BCG vaccine is expected to restrain the market growth.
Depending on drug type, the immune BCG segment is the highest revenue contributor and is also expected to exhibit the fastest growth rate of 4.9%. This is attributed to the wider use of BCG vaccine to acquire immunity against tuberculosis and absence of substitute to BCG vaccines currently.
Asia-Pacific was the highest revenue contributor in the global BCG vaccines sales market share, accounting for 70% of the total market in 2017. However, LAMEA is expected to grow at the highest rate, owing to the number of developing nations present in this region, rise in technological advancements in the vaccines procured, increased awareness, and higher disposable income.
Based on usage, the tuberculosis segment occupied the largest share of the market in 2017 and is expected to grow at the highest rate during the forecast period. Factors such as high prevalence of tuberculosis and large number of deaths due to tuberculosis globally significantly contribute toward the growth of this segment.
By end user, the pediatrics occupied the largest share in 2017, owing to increase in adoption of BCG vaccines due to its efficacy to prevent tuberculosis in pediatrics.
Key Findings of the BCG Vaccines Sales Market:
Europe occupied one-third share of the global BCG vaccines sales market in 2017.
The tuberculosis segment is anticipated to grow with the highest CAGR throughout the forecast period.
The pediatrics segment accounted for three-fourth share of the market in 2017.
Immune BCG is anticipated to grow at the highest rate during the analysis period.
The major companies profiled in this report include AJ Vaccines, China National Pharmaceutical Group Corporation (Sinopharm), Greensignal Bio Pharma Limited, Intervax Ltd, Japan BCG Laboratory, Merck & Company Inc, Sanofi S.A., Serum Institute of India Pvt. Ltd., and Statens Serum Institute.
BCG vaccine is a live attenuated vaccine used for the prevention of tuberculosis. The types of BCG drugs include immune BCG and therapy BCG. The BCG vaccines sales market growth has increased owing to gained prominence in the recent years due to high prevalence of tuberculosis worldwide and rise in number of drug-resistant tuberculosis cases. However, replacement for BCG vaccine is expected to restrain the market growth.
Depending on drug type, the immune BCG segment is the highest revenue contributor and is also expected to exhibit the fastest growth rate of 4.9%. This is attributed to the wider use of BCG vaccine to acquire immunity against tuberculosis and absence of substitute to BCG vaccines currently.
Asia-Pacific was the highest revenue contributor in the global BCG vaccines sales market share, accounting for 70% of the total market in 2017. However, LAMEA is expected to grow at the highest rate, owing to the number of developing nations present in this region, rise in technological advancements in the vaccines procured, increased awareness, and higher disposable income.
Based on usage, the tuberculosis segment occupied the largest share of the market in 2017 and is expected to grow at the highest rate during the forecast period. Factors such as high prevalence of tuberculosis and large number of deaths due to tuberculosis globally significantly contribute toward the growth of this segment.
By end user, the pediatrics occupied the largest share in 2017, owing to increase in adoption of BCG vaccines due to its efficacy to prevent tuberculosis in pediatrics.
Key Findings of the BCG Vaccines Sales Market:
Europe occupied one-third share of the global BCG vaccines sales market in 2017.
The tuberculosis segment is anticipated to grow with the highest CAGR throughout the forecast period.
The pediatrics segment accounted for three-fourth share of the market in 2017.
Immune BCG is anticipated to grow at the highest rate during the analysis period.
The major companies profiled in this report include AJ Vaccines, China National Pharmaceutical Group Corporation (Sinopharm), Greensignal Bio Pharma Limited, Intervax Ltd, Japan BCG Laboratory, Merck & Company Inc, Sanofi S.A., Serum Institute of India Pvt. Ltd., and Statens Serum Institute.
Note: Product cover images may vary from those shown
4 of 4
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
